Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff OncologyCRDF +0.52%31 EV-to-EBITDA is -0.46 as of Aug. 01, 2026. GuruFocus rates CRDF with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 411 Biotechnology companies, Cardiff Oncology ranks worse than 243308.76% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cardiff Oncology's enterprise value is $21.45 Mil.
Cardiff Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-46.49 Mil. Therefore, Cardiff Oncology's EV-to-EBITDA for today is -0.46.
The historical rank and industry rank for Cardiff Oncology's EV-to-EBITDA or its related term are showing as below:
CRDF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.52 Med: -0.68 Max: 2.08
Current: -0.46
During the past 13 years, the highest EV-to-EBITDA of Cardiff Oncology was 2.08. The lowest was -29.52. And the median was -0.68.
CRDF's EV-to-EBITDA is ranked worse than 100% of 411
companies
in the Biotechnology industry
Industry Median: 12.05
vs CRDF: -0.46
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cardiff Oncology's PE Ratio (TTM) for today is calculated as:
Cardiff Oncology's share price for today is $0.8594.
Cardiff Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.670.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cardiff Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardiff Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's EV-to-EBITDA falls into.
Cardiff Oncology's current Enterprise Value is $21.45 Mil.
Cardiff Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a EV-to-EBITDA of -0.46 as of Aug. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cardiff Oncology. According to the industry distribution chart, Cardiff Oncology ranks #999999 out of 411 companies in the Biotechnology industry.
Is Cardiff Oncology's EV-to-EBITDA too high?
Cardiff Oncology's current EV-to-EBITDA is -0.46. Based on the distribution chart, Cardiff Oncology ranks #999999 out of 411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardiff Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's EV-to-EBITDA compare to MNOV and PMVP?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #999999 out of 411 companies for EV-to-EBITDA. This places Cardiff Oncology in the lower half of its industry. The industry median EV-to-EBITDA is 12.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.05, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cardiff Oncology. For the Biotechnology industry, the median EV-to-EBITDA is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current EV-to-EBITDA is -0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current EV-to-EBITDA of -0.46. The current EV-to-EBITDA is -0.46. Cardiff Oncology's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current EV-to-EBITDA is -0.46 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
31GF Score
Get the complete analysis for CRDF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
